±èÁÖÇ×
¾ÏÁ¤¹ÐÀÇ·á¼¾ÅÍÀå
¼Ò
¼Ó
: ºÐ´çÂ÷º´¿ø
Àü¹®ºÐ¾ß : Æó¾Ï, µÎ°æºÎ¾Ï, ½Äµµ¾Ï
Á÷
ˤ
: ±³¼ö(¾ÏÁ¤¹ÐÀÇ·á¼¾ÅÍÀå)
¸Þ
ÀÏ
:
ºñ°ø°³
Àü
È
:
1577-4488
ÆÑ
½º
:
ÁÖ
¼Ò
:
°æ±âµµ ¼º³²½Ã ºÐ´ç±¸ ¾ßžµ¿ 351¹øÁö
ȨÆäÀÌÁö:
ÅǸ޴º
ÁÖ¿ä¹ßÇ¥³í¹®
¹øÈ£
±¸ºÐ
Á¦¸ñ
´Ù¿î·Îµå
104
ÇØ¿Ü
A phase I trial of gefitinib and nimotuzumab in patients with advanced non-small cell lung cancer (NSCLC)
103
ÇØ¿Ü
TRAIL/MEKK4/p38/HSP27/Akt survival network is biphasically modulated by the Src/CIN85/c-Cbl complex
102
±¹³»
EGFR Polymorphism as a Predictor of Clinical Outcome in Advanced Lung Cancer Patients Treated with EGFR-TKI
101
ÇØ¿Ü
Phase II Study of Cisplatin with Irinotecan as Induction Chemotherapy Followed by Chemoradiotherapy for Unresectable Stage III Non-small Cell Lung Cancer
100
ÇØ¿Ü
The efficacy and toxicity of S-1 and cisplatin as first-line chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma
99
ÇØ¿Ü
Additional diagnostic value of tumor markers in cytological fluid for diagnosis of non-small-cell lung cancer
98
ÇØ¿Ü
Activation of IL-6R/JAK1/STAT3 signaling induces De Novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation
97
±¹³»
Treatment Outcome of Patients with Anaplastic Thyroid Cancer: A Single Center Experience
96
ÇØ¿Ü
Overexpression of Class III Beta Tubulin and Amplified HER2 Gene Predict Good Response to Paclitaxel and Trastuzumab Therapy.
95
ÇØ¿Ü
HSP27 modulates survival signaling networks in cells treated with curcumin and TRAIL
1
2
3
4
5
6
7
8
9
10
Copyright ¨Ï chamc, All rights reserved.
ºü¸£°í Æí¸®ÇÑ ÀÎÅÍ³Ý Áø·á¿¹¾à
Àüȹ®ÀÇ
°³²Â÷º´¿ø 02.3468.3000
ºÐ´çÂ÷º´¿ø 031.780.5000
Â÷¿ò 02.3015.5300
±¸¹ÌÂ÷º´¿ø 054.450.9700
´ë±¸¿©¼ºÂ÷º´¿ø 02.222.4200
°³²°ÇÁø¼¾ÅÍ 02.2191.3900
ºÐ´çÁ¾ÇÕ°Ç°ÁõÁø¼¾ÅÍ 031.780.5940
½ºÆ÷·º½º °ÇÁø¼¾ÅÍ 02.3473.2111
±¸¹ÌÂ÷º´¿ø°ÇÁø¼¾ÅÍ 054.450.9800
ȨÆäÀÌÁö°ü¸®ÀÚ 031.780.1729